Detailed price information for Relay Therapeutics Inc (RLAY-Q) from The Globe and Mail including charting and trades.
Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results